DGAP-News Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis
DGAP-News: ABIVAX / Key word(s): Study
Abivax completes induction treatment of last patient in ABX464 phase 2b clinical study in ulcerative colitis
- 16-weeks induction treatment with ABX464 in phase 2b clinical study in ulcerative colitis completed for the 254 patients enrolled, with reduction of Total Mayo Score after 8 weeks as primary endpoint
- Top-line data of induction phase to become available in the second half of May 2021
- 48-weeks maintenance treatment with ABX464 in phase 2b clinical study in ulcerative colitis now fully enrolled, with top-line data to become available in Q1 2022
- Start of clinical phase 3 program in ulcerative colitis expected by year end
- KOL webcast scheduled on Tuesday, April 20, 2021 at 1:30 pm CEST with Prof. Bruce Sands, M.D., M.S. to discuss ulcerative colitis, existing and future treatment options, and current unmet needs
PARIS, France, April 14, 2021 - 6:30 p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces the completion of 16-weeks of induction treatment with different doses of ABX464 or placebo in its clinical phase 2b study for the treatment of moderate-to-severe ulcerative colitis (UC). Top-line data will become available in the second half of next month.
The first patient was enrolled into the double-blind, placebo-controlled, dose ranging phase 2b clinical trial with ABX464 in UC in August 2019 and recruitment of 254 patients was completed in December 2020. The last patient has now completed the 16-weeks induction treatment.
Ahead of the data read-out, the Company will host a webcasted key opinion leader (KOL) event on Tuesday, April 20, 2021 at 1:30 pm CEST (7:30 am EDT) with Prof. Bruce Sands, M.D., M.S., Chief of the Division of Gastroenterology at the Mount Sinai School of Medicine in New York, NY. Dr. Sands will discuss UC, current and future treatments and unmet needs, and Abivax's senior management will provide an update on the Company and the potential of ABX464 to become a safe and effective new treatment option.